232 related articles for article (PubMed ID: 17188962)
21. How specific are "target-specific" drugs? Celecoxib as a case in point.
Sadée W; Bohn L
Mol Interv; 2006 Aug; 6(4):196-8. PubMed ID: 16960141
[TBL] [Abstract][Full Text] [Related]
22. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
[No Abstract] [Full Text] [Related]
23. [Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills].
MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035421
[No Abstract] [Full Text] [Related]
24. Risks and benefits of celecoxib to prevent colorectal adenomas.
Andersohn F; Suissa S; Garbe E
N Engl J Med; 2006 Nov; 355(22):2371; author reply 2371-3. PubMed ID: 17135594
[No Abstract] [Full Text] [Related]
25. Does the dose make the poison?
Harris RE
Science; 2005 Apr; 308(5719):203. PubMed ID: 15821073
[No Abstract] [Full Text] [Related]
26. The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.
Reuben SS
Acta Anaesthesiol Scand; 2005 Mar; 49(3):424; author reply 425. PubMed ID: 15752415
[No Abstract] [Full Text] [Related]
27. COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Meechan J
Br J Oral Maxillofac Surg; 2006 Apr; 44(2):163-5. PubMed ID: 16191457
[No Abstract] [Full Text] [Related]
28. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain.
Chelly JE; Nissen CW; Rodgers AJ; Smugar SS; Tershakovec AM
Curr Med Res Opin; 2007 Jan; 23(1):195-206. PubMed ID: 17207303
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib shown effective in preventing colon polyps.
Nelson NJ
J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
[No Abstract] [Full Text] [Related]
31. A tale of two coxibs.
Hegmann T
JAAPA; 2005 Mar; 18(3):14, 17. PubMed ID: 15789666
[No Abstract] [Full Text] [Related]
32. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA
Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468
[TBL] [Abstract][Full Text] [Related]
33. Balancing the cyclooxygenase portfolio.
Armstrong PW
CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
[No Abstract] [Full Text] [Related]
34. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
Messerli FH; Sichrovsky T
Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
[No Abstract] [Full Text] [Related]
35. Adverse cardiovascular effects of rofecoxib.
Furberg CD
N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
[No Abstract] [Full Text] [Related]
36. The Vioxx fallout.
Palmer K
Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
[No Abstract] [Full Text] [Related]
37. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Manzano A; Pérez-Segura P
ScientificWorldJournal; 2012; 2012():327341. PubMed ID: 22649288
[TBL] [Abstract][Full Text] [Related]
38. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
[TBL] [Abstract][Full Text] [Related]
39. Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis.
Sato K; Yamada E; Uehara Y; Takagi H; Mori M
Clin Pharmacol Ther; 2006 Nov; 80(5):554-5. PubMed ID: 17112814
[No Abstract] [Full Text] [Related]
40. Cerebrovascular events after discontinuation of rofecoxib treatment.
Andersohn F
Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
